PMID- 12727113
OWN - NLM
STAT- MEDLINE
DCOM- 20040112
LR  - 20190607
IS  - 1525-0016 (Print)
IS  - 1525-0016 (Linking)
VI  - 7
IP  - 4
DP  - 2003 Apr
TI  - Induction of specific antitumor immunity in the mouse with the electrofusion 
      product of tumor cells and dendritic cells.
PG  - 498-505
AB  - Dendritic cells (DCs) are potent antigen-presenting cells capable of inducing 
      primary T-cell responses. Several immunotherapy treatment strategies involve 
      manipulation of DCs, both in vivo and ex vivo, to promote the immunogenic 
      presentation of tumor-associated antigens. In this study, an electrofusion 
      protocol was developed to induce fusion between tumor cells and allogeneic bone 
      marrow-derived DCs. Preimmunization with irradiated electrofusion product was 
      found to provide partial to complete protection from tumor challenge in the 
      murine Renca renal cell carcinoma model and the B16 and M3 melanoma models. 
      Vaccinated survivors developed specific immunological memory and were able to 
      reject a subsequent rechallenge with the same tumor cells but not a syngeneic 
      unrelated tumor line. Antitumor protection in the B16 model was accompanied by 
      the development of a polyclonal cytotoxic T-lymphocyte response against defined 
      melanoma-associated antigens. The therapeutic potential of this type of approach 
      was suggested by the ability of a Renca-DC electrofusion product to induce tumor 
      rejection in a substantial percentage of hosts (60%) bearing pre-established 
      tumor cells. These results indicate that treatment with electrofused tumor cells 
      and allogeneic DCs is capable of inducing a potent antitumor response and could 
      conceivably be applied to a wide range of cancer indications for which 
      tumor-associated antigens have not been identified.
FAU - Siders, William M
AU  - Siders WM
AD  - Genzyme Molecular Oncology, 31 New York Ave., Framingham, Massachusetts 01701, 
      USA.
FAU - Vergilis, Kristin L
AU  - Vergilis KL
FAU - Johnson, Carrie
AU  - Johnson C
FAU - Shields, Jacqueline
AU  - Shields J
FAU - Kaplan, Johanne M
AU  - Kaplan JM
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/metabolism
MH  - *Cancer Vaccines/immunology
MH  - Cell Fusion/*methods
MH  - Dendritic Cells/*immunology/metabolism
MH  - *Electroporation
MH  - Immunotherapy/methods
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred DBA
MH  - Neoplasms, Experimental/*immunology/*prevention & control
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Tumor Cells, Cultured
EDAT- 2003/05/03 05:00
MHDA- 2004/01/13 05:00
CRDT- 2003/05/03 05:00
PHST- 2003/05/03 05:00 [pubmed]
PHST- 2004/01/13 05:00 [medline]
PHST- 2003/05/03 05:00 [entrez]
AID - S1525-0016(03)00044-3 [pii]
AID - 10.1016/s1525-0016(03)00044-3 [doi]
PST - ppublish
SO  - Mol Ther. 2003 Apr;7(4):498-505. doi: 10.1016/s1525-0016(03)00044-3.